

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

NCT07248280

Status	RECRUITING
Phase	Phase 3
Sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Enrollment	260 participants

Key Eligibility Criteria

Inclusion (2)

- years and over, requiring an ambulatory surgery
- at high risk of post-operative nausea and vomiting defined by at least 3 factors from the Apfel score, calculated just prior to the surgery (female sex; non smoker; previous nausea or vomiting post-op., or motion sickness; expected opioid consumption in postoperative care).

Exclusion (3)

- Refusal or unable to consent
- Suspected or documented allergy to aprepitant (emend)
- Concomitant use of medication interacting via the cytochrome CYP3A4 with aprepitant (pimozide, terfenadine, astemizole, comtadin or cisapride).

Locations (1 total)

Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada